Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 7,249 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo group Clear all
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

NCT02288273
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Bydureon, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
29
States / cities
Anaheim, California • Chino, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 13, 2026, 10:43 PM EDT
Terminated Phase 2 Interventional

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis

NCT02606994
View directory record Official record
Conditions
Mucositis, Neoplasms
Interventions
Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse
Drug
Lead sponsor
Oral Defense, LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 13, 2026, 10:43 PM EDT
Active, not recruiting Phase 2 Interventional

Reducing Innate Inflammation in New Onset Type 1 Diabetes

NCT04335656
View directory record Official record
Conditions
Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus
Interventions
Lactiplantibacillus plantarum, Placebo
Dietary Supplement · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 13, 2026, 10:43 PM EDT
Recruiting Phase 2 Interventional

Detoxification of the Liver In PSC (Dolphin)

NCT05835505
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
BRS201, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

NCT03095456
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Interventions
Revefenacin, Spiriva Handihaler®, Placebo for Revefenacin, Placebo for Spiriva Handihaler®
Drug · Combination Product
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 3 Interventional

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

NCT00118729
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
GW685698X Aqueous Nasal Spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Woodstock, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT01451827
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan MR, Tolvaptan IR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

NCT00609466
View directory record Official record
Conditions
Bunionectomy, Pain, Postoperative Pain, Acute Pain
Interventions
CG5503 IR, Morphine, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Pasadena, Maryland • Austin, Texas • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 13, 2026, 10:43 PM EDT
Recruiting Phase 1 Interventional

SGLTi, Hepatic Glucose Production and Ketogenesis

NCT05960656
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 13, 2026, 10:43 PM EDT
Terminated Phase 2 Interventional Results available

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

NCT01013870
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.

NCT01920854
View directory record Official record
Conditions
Kidney Failure, Chronic Therapy; Hemodialysis
Interventions
soluble ferric pyrophosphate, Placebo
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of NAC in Alleviation of Hangover Symptoms

NCT02541422
View directory record Official record
Conditions
Hangover Symptoms, NAC
Interventions
N Acetyl Cysteine, placebo
Dietary Supplement · Other
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 13, 2026, 10:43 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

NCT04811131
View directory record Official record
Conditions
Vitiligo
Interventions
ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment, NB-UVB phototherapy sham treatment
Drug · Device
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Rolling Meadows, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tanezumab for Chronic Low Back Pain

NCT02528253
View directory record Official record
Conditions
Low Back Pain
Interventions
Placebo to Week 16; tanezumab 5mg SC, Placebo to Week 16, tanezumab 10 mg SC, Tanezumab 5 mg SC, Tanezumab 10 mg SC, Tramadol PR oral
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
179
States / cities
Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HELP-HY: Health Education and sLeep Program in HYpertension

NCT03255746
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Sleep Enhancement, Health Education
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

NCT00715273
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 70 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 13, 2026, 10:43 PM EDT
Terminated Phase 2 Interventional Results available

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

NCT00939094
View directory record Official record
Conditions
Neuropathic Pain, Mechanical Hypersensitivity
Interventions
AZD2066, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 13, 2026, 10:43 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT05911841
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LY3454738, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Fort Smith, Arkansas • North Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

NCT01677754
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Anaheim, California • Fullerton, California • Lomita, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

NCT02708095
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery

NCT03482973
View directory record Official record
Conditions
Coronary Artery Disease, Sternal Pain
Interventions
Bupivacaine Group, Placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 13, 2026, 10:43 PM EDT
Not listed Phase 2 Interventional

Polydatin Injectable (HW6) for Shock Treatment

NCT01780129
View directory record Official record
Conditions
Shock, Hemorrhagic, Shock, Traumatic, Shock, Septic
Interventions
Polydatin Injectable
Drug
Lead sponsor
Neptunus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 13, 2026, 10:43 PM EDT
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 13, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time-Restricted Feeding Plus Resistance Training in Active Females

NCT03404271
View directory record Official record
Conditions
Healthy Active Females
Interventions
Beta-hydroxy beta-methylbutyrate, Resistance Training, Protein Supplementation, Time-Restricted Feeding
Dietary Supplement · Other · Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 13, 2026, 10:43 PM EDT